Pelafen® Med 20 mg/2,5 ml syrup
medicinal product
Common cold, immunity
Indications for use
Pelafen® MED syrup is a traditional herbal medicinal product used for symptomatic treatment of common cold. The product is a traditional herbal medicinal product to be used in specified indications exclusively based upon long-standing use.
Pelafen® MED is intended to be used in adults, adolescents, and children over the age of 6.
2.5 ml of the syrup contains 20 mg of dry extract (4-25:1) of Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix (geranium root); extraction solvent: ethanol 11% (m/m). Excipients with known effect: sorbitol. One dose contains 625.1 mg of sorbitol (liquid sorbitol contains 70% of sorbitol) and 893 mg of maltitol.
Form: syrup
Dark red product; contains natural ingredients, which can lead to the formation of a precipitate.
Pelafen® MED should not be used in case of: hypersensitivity to the active ingredient (pelargonium root extract) or any of the excipients.
Phytopharm Klęka S.A., Klęka 1, 63-040 Nowe Miasto nad Wartą
Dosage and route of administration
Who?
Dose
When?
2.5 ml of syrup
2 times per day
Adolescents over the age of 12, adults, and the elderly
2.5 ml of syrup
3 times per day
Not recommended for children below the age of 6.
Patients with renal and/or hepatic insufficiency: No data available on the use of Pelafen® MED in patients with hepatic and/or renal insufficiency.
Method of administration: oral use.
Pelafen® MED contains a graduated cup, which is used for measuring out the appropriate amount of the syrup.
Shake the bottle before use.
If, despite using Pelafen® MED, the symptoms persist for more than 7 days, consult a doctor or a pharmacist.
Do not take Pelafen® MED after the expiry date. Before using the drug, read the patient information leaflet.
Want to learn more?
This is a medicine. For your safety, use it in accordance with the package leaflet. Pay attention to the contraindications. If in doubt, consult your doctor or pharmacist.
Traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.
PML/09/2024/3
